Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | PRKCA | P17252 | 6/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.31 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL915745 | 0.92 | LMNA (0.33) | LMNAKMT2ASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL915963 | 0.88 | LMNA (0.41) | LMNAKMT2ASMN1; SMN2GAAPRKCA | |
| SCHEMBL15992178 | 0.87 | PSMB8 (0.32) | GAAALDH1A1 | |
| SCHEMBL916334 | 0.86 | MGLL (0.32) | — | |
| SCHEMBL15991892 | 0.83 | MAPT (0.38) | LMNAKMT2ASMN1; SMN2GAAMAPT | |
| SCHEMBL21320819 | 0.83 | LMNA (0.49) | LMNAKMT2ASMN1; SMN2GAAPRKCA | |
| SCHEMBL21320817 | 0.83 | LMNA (0.49) | LMNAKMT2ASMN1; SMN2GAAPRKCA | |
| SCHEMBL21320421 | 0.83 | LMNA (0.49) | LMNAKMT2ASMN1; SMN2GAAPRKCA | |
| SCHEMBL3109446 | 0.83 | LMNA (0.49) | LMNAKMT2ASMN1; SMN2GAAPRKCA | |
| SCHEMBL15991400 | 0.82 | PTGS1 (0.41) | LMNASMN1; SMN2GAAMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372881-B2 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110009483-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-7777070-B2 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1919859-B1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID AND USE | XENOPORT INC (US) | 2010-06-02 | — | — | EP | disclosed |
| US-20100036148-A1 | Acyloxyalkyl Carbamate Prodrugs of Tranexamic Acid, Methods of Synthesis and Use | XENOPORT, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-7592369-B2 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-20080153898-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. | 2008-06-26 | — | — | US | disclosed |
| EP-1919859-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | Xenoport, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| US-7351740-B2 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070027210-A1 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. | 2007-02-01 | — | — | US | disclosed |
| WO-2007002013-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027210-A1 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | ACMSD, APEH, CPS1 | LMNA 946/4885KMT2A 1530/4885SMN1; SMN2 3931/4885 |
| US-20110009483-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | ACMSD, APEH, CPS1 | LMNA 946/4885KMT2A 1530/4885SMN1; SMN2 3931/4885 |
| US-20080153898-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | ACMSD, APEH, CPS1 | LMNA 946/4885KMT2A 1530/4885SMN1; SMN2 3931/4885 |
| US-20100036148-A1 | Acyloxyalkyl Carbamate Prodrugs of Tranexamic Acid, Methods of Synthesis and Use | ACMSD, APEH, CPS1 | LMNA 946/4885KMT2A 1530/4885SMN1; SMN2 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.